anti-BCL2-Like 12 (Proline Rich) (BCL2L12) Antikörper

Human BCL2-Like 12 (Proline Rich) (BCL2L12) Interaktionspartner

1. Increased BCL2L12 v.4 mRNA expression was associated with markers of unfavorable prognosis namely, advanced tumor, ER- (p=0.015)/PR-, Ki-67-positivity and high NPI (Nottingham prognostic index) score

2. Bcl2L12 is positively correlated with Th2 cytokine levels in the nasal mucosa of chronic rhinosinusitis with accompanying nasal allergy (CRSa) patients. Bcl2L12 contributes to the Th2 polarization, which may be a novel therapeutic target in the treatment of CRSa.

3. Bcl2L12 plays a crucial role in the induction of Th2 polarization and allergic response in the intestine. The Bcl2L12 in CD4(+) T cells may be a potential target for the treatment of food allergy.

4. Bcl2L12 is a critical factor in the induction of aberrant Th2 polarization by upregulating Th2 responses and downregulating Th2 cell apoptosis

5. Peripheral CD4+ T cells express high levels of Bcl2L12 in patients with ulcerative colitis. Bcl2L12 mediates PAR2-induced Th2 cell development to promote inflammation in the pathogenesis of ulcerative colitis.

6. Activation of PAR2 inhibits the expression of IL-10 in B cells, which can be reversed by treating B cells with Bcl2L12 shRNA-carrying liposomes.

7. BCL2L12 is a new prognostic biomarker for favorable outcome in diffuse large B-cell lymphoma patients on rituximab.

8. stress hormone cortisol suppresses p53 in hepatocellular carcinoma via enhancing Bcl2L12 expression

9. TNF-alpha suppresses IL-10 in peripheral B cells via up-regulating Bcl2L12 in patients with ulcerative colitis.

10. miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer cells via targeting BCL2, BCL2L12 and Mcl-1.

11. Identify 50 novel BCL2L12 splice variants in human tumor cell lines.

12. Results show that high Bcl2L12 mRNA expression was associated with the high-grade breast cancer and triple-negative (TNBC) subtype. Also, the interplay between Bcl2L12 and its variant may be associated with high lymph node metastasis in non-TNBC tumors.

13. CD82 regulated BCL2L12 expression via STAT5A and AKT signaling and stimulated proliferation and engrafting of leukemia cells.

14. Bcl2L12 retains a BH3-like domain, which is important for its anti-apoptotic property.

15. Data indicate that BCL2-like 12 (proline rich) protein BCL2L12 mRNA levels can distinguish women with breast cancer from healthy controls.

16. Data indicate that BCL2L12 expression levels were associated with poor disease-free survival of the high-grade TaT1 bladder cancer patients.

17. Bcl2L12 was previously shown to inhibit apoptosis through binding to caspase 7.

18. cisplatin treatment induced a time-dependent apoptosis in glioblastoma cells, at least partially via downregulation of BCL2L12 gene expression.

19. Acute myeloid leukemia patients have a lower level of BCL2L12 gene expression.

20. Protein made from F17F mutant BCL2L12 transcript bound p53, inhibited UV-induced apoptosis more efficiently than WT BCL2L12, and reduced endogenous p53 target gene transcription.

Mouse (Murine) BCL2-Like 12 (Proline Rich) (BCL2L12) Interaktionspartner

1. Bcl2L12 plays a crucial role in the induction of Th2 polarization and allergic response in the intestine. The Bcl2L12 in CD4(+) T cells may be a potential target for the treatment of food allergy.

2. nuclear Bcl2L12 physically and functionally interacts with the p53 tumor suppressor

3. Data show that apoptotic defect in Irf3(-/-)Bcl2l12(-/-) MEFs was rescued by the ectopic expression of Bcl2L12, but not IRF3.